Evidence map›Paper›PMID 38702808›Full record

ArticleStem cell research & therapy2024

Monocytes prevent apoptosis of iPSCs and promote differentiation of kidney organoids.

Ekaterina Pecksen, Sergey Tkachuk, Cristoph Schröder, Marc Vives Enrich, Anindita Neog, Cory P Johnson, Niko Lachmann, Hermann Haller, Yulia Kiyan

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Organoids and tissue/organ chips.Stem cell research & therapy · 2024
    Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ekaterina PecksenClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Sergey TkachukClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Cristoph SchröderClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Marc Vives EnrichClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Anindita NeogClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Cory P JohnsonMount Desert Island Biological Laboratory, Bar Harbor, Maine, USA.
Niko LachmannDepartment of Pediatric Pneumology Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
Hermann HallerClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany.
Yulia KiyanClinics for Kidney and Hypertension Disease, Hannover Medical School, Hannover, Germany. kiian.ioulia@mh-hannover.de.ORCID 0000-0002-2063-6327

Funding

The Maine Biomedical Research Network (INBRE)P20GM103423 · NIGMS · MOUNT DESERT ISLAND BIOLOGICAL LAB · PI JAMES A COFFMAN · 2012 to 2026
$60.0M
NIGMS NIH HHS P20 GM103423
6 · The paper itself

Abstract

backgroundInduced pluripotent stem cells (iPSCs)-derived kidney organoids are a promising model for studying disease mechanisms and renal development. Despite several protocols having been developed, further improvements are needed to overcome existing limitations and enable a wider application of this model. One of the approaches to improve the differentiation of renal organoids in vitro is to include in the system cell types important for kidney organogenesis in vivo, such as macrophages. Another approach could be to improve cell survival. Mesodermal lineage differentiation is the common initial step of the reported protocols. The glycogen synthase kinase-3 (GSK-3) activity inhibitor, CHIR99021 (CHIR), is applied to induce mesodermal differentiation. It has been reported that CHIR simultaneously induces iPSCs apoptosis that can compromise cell differentiation. We thought to interfere with CHIR-induced apoptosis of iPSCs using rapamycin.

methodsDifferentiation of kidney organoids from human iPSCs was performed. Cell survival and autophagy were analyzed using Cell counting kit 8 (CCK8) kit and Autophagy detection kit. Cells were treated with rapamycin or co-cultured with human monocytes isolated from peripheral blood or iPSCs-macrophages using a transwell co-culture system. Monocyte-derived extracellular vesicles (EVs) were isolated using polyethylene glycol precipitation. Expression of apoptotic markers cleaved Caspase 3, Poly [ADP-ribose] polymerase 1 (PARP-1) and markers of differentiation T-Box Transcription Factor 6 (TBX6), odd-skipped related 1 (OSR1), Nephrin, E-Cadherin, Paired box gene 2 (Pax2) and GATA Binding Protein 3 (Gata3) was assessed by RT-PCR and western blotting. Organoids were imaged by 3D-confocal microscopy.

resultsWe observed that CHIR induced apoptosis of iPSCs during the initial stage of renal organoid differentiation. Underlying mechanisms implied the accumulation of reactive oxygen species and decreased autophagy. Activation of autophagy by rapamacin and by an indirect co-culture of differentiating iPSCs with iPSCs-macrophages and human peripheral blood monocytes prevented apoptosis induced by CHIR. Furthermore, monocytes (but not rapamycin) strongly promoted expression of renal differentiation markers and organoids development via released extracellular vesicles.

conclusionOur data suggest that co-culturing of iPSCs with human monocytes strongly improves differentiation of kidney organoids. An underlying mechanism of monocytic action implies, but not limited to, an increased autophagy in CHIR-treated iPSCs. Our findings enhance the utility of kidney organoid models.

Indexed as

ApoptosisCell DifferentiationInduced Pluripotent Stem CellsKidneyMonocytesOrganoidsAutophagyCoculture TechniquesHumansMacrophagesPyridinesPyrimidinesSirolimusChir 99021PyridinesPyrimidinesSirolimusApoptosisAutophagyiPSCsiPSCs-macrophagesKidney organoidsMonocytes

Identifiers

PMID38702808
PMCPMC11069262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.